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prostate cancer nodal Staging: 
Using Deep Learning to predict 
68Ga-pSMA-positivity from ct 
imaging Alone
A. Hartenstein1, f. Lübbe1, A. D. J. Baur1, M. M. Rudolph1, c. furth2, W. Brenner  2, 
H. Amthauer2, B. Hamm1, M. Makowski1,4,5 & t. penzkofer1,3,5*
Lymphatic spread determines treatment decisions in prostate cancer (PCa) patients. 68Ga-PSMA-PET/
ct can be performed, although cost remains high and availability is limited. therefore, computed 
tomography (ct) continues to be the most used modality for pca staging. We assessed if convolutional 
neural networks (CNNs) can be trained to determine 68Ga-PSMA-PET/CT-lymph node status from CT 
alone. In 549 patients with 68Ga-PSMA PET/CT imaging, 2616 lymph nodes were segmented. Using 
PET as a reference standard, three CNNs were trained. Training sets balanced for infiltration status, 
lymph node location and additionally, masked images, were used for training. cnns were evaluated 
using a separate test set and performance was compared to radiologists’ assessments and random 
forest classifiers. Heatmaps maps were used to identify the performance determining image regions. 
The CNNs performed with an Area-Under-the-Curve of 0.95 (status balanced) and 0.86 (location 
balanced, masked), compared to an AUC of 0.81 of experienced radiologists. Interestingly, CNNs 
used anatomical surroundings to increase their performance, “learning” the infiltration probabilities 
of anatomical locations. in conclusion, cnns have the potential to build a well performing ct-based 
biomarker for lymph node metastases in PCa, with different types of class balancing strongly affecting 
cnn performance.
Prostate cancer (PCa) is the most common malignant cancer in men worldwide, and the second most common 
cause of cancer related death in men1. Patients with intermediate or high-risk PCa undergo regular staging exami-
nations in order to determine if the tumor has spread beyond the prostate. As treatment success is highly depend-
ent on the presence of systemic spread2,3, staging procedures with high sensitivity and specificity are necessary.
Standard of care imaging for PCa staging typically includes contrast-enhanced computed tomography (CT) 
and Technetium-99m-methylene diphosphonate bone scans4,5. Despite the continued recommendation of CT in 
staging, it has been shown that predicting lymph node infiltration (LNI) with CT scans is not very reliable6,7, with 
one study reporting a sensitivity and specificity of only 42% and 82%8. This low performance is most likely due to 
the limited morphological criteria used to define a lymph node as positive for infiltration, with size being the most 
relevant9. A threshold of 8–10 mm is often used despite the fact that 80% of lymph node metastases are less than 
8 mm in the short axis10. Further criteria, such as status of hilum fat, nodal shape, and enhancement characteris-
tics are used to aid diagnosis, but it remains difficult to exclude LNI in large benign hyperplastic nodes or detect 
it in small nodes below the size threshold11.
In 2012 imaging agents binding to Prostate Specific Membrane Antigen (PSMA) were introduced, leading 
to the development of PSMA PET/CT8. PSMA, an integral membrane glycoprotein expressed 100–1000 fold on 
membranes of PCa cells compared to prostate cells, has been shown to correlate with aggressive disease, disease 
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recurrence, and metastasis12–14, and radio-tracer targeting of PSMA in conjunction with CT has been shown in a 
systematic review and meta-analysis of 5 studies to predict LNI with a sensitivity and specificity of 80% and 97% 
respectively15. PSMA PET/CT has been used to detect PCa in the prostate, soft tissue, and bone, and has been 
shown to detect LNI in nodes even under 10 mm in size, with one study reporting a 60% detection rate for nodes 
between 2–5 mm16,17.
Even though PSMA PET/CT has proven to be very valuable in PCa staging, it remains of limited availability 
and hybrid imaging such as PET/CT is associated with high costs. The goal of this study was to evaluate – using 
68Ga-PSMA PET/CT as a reference standard – if it is possible to elucidate the status of lymph nodes based on 
contrast-enhanced CT images alone using deep learning in the form of convolutional neural networks (CNNs).
Materials and Methods
imaging datasets. Inclusion criteria for this retrospective study was the availability of a 68Ga-PSMA PET/
CT examination with parallel contrast-enhanced CT examination performed between September 2013 and April 
2017. All patients had histopathologically verified prostate cancer that warranted staging examinations. Exclusion 
criteria were non-contrast or low-dose only CT examination, insufficient image quality, and follow-up studies 
(only the first 68Ga-PSMA PET/CT of each patient was included). Of 738 patients, 549 patients (68.7 ± 7.54 
[45–87] years, PSA 20.9 ± 94.6 [0–1423] ng/ml) fulfilled our inclusion criteria. The study was approved by the 
Charité Ethics Committee, and due to the retrospective design, the need for informed written consent was waived 
by the same review board, in accordance with institutional guidelines and regulations. The study was performed 
in accordance with the Declaration of Helsinki.
All patients had received 68Ga-PSMA PET/CT examinations for clinical purposes during the course of treat-
ment. A standard 68Ge/68Ga generator (Eckert and Ziegler Radiopharma GmbH, Berlin, Germany) was used for 
68Ga production, and PSMA- HBED-CC (ABX GmbH, Radeberg, Germany) labelling with 68Ga was performed 
according to the previously described method18. All PET/CT images were acquired using a Gemini Astonish 
TF 16 PET/CT scanner (Phillips Medical Systems, Best, The Netherlands) after intravenous injection of 68Ga- 
PSMA-HBED-CC19 using 3-D acquisition mode for all PET scans.
Semi-automated manual three dimensional segmentation of lymph nodes was performed using the MITK 
software suite (MITK v. 2016.3.0, DKFZ, Heidelberg, Germany)20. Using the PSMA PET image as ground truth, 
a label of positive or negative for tumor infiltration was generated for each lymph node in consensus of two radi-
ologists experienced in hybrid imaging, correlated with SUVmax. Figure 1 shows an example of a 68Ga-PSMA 
PET/CT full body scan and two selected lymph nodes, one positive and one negative for infiltration. In addition 
to the tumor infiltration label, the position of each lymph node in the body was manually assigned a categorical 
variable from a set of 9 possible categories (inguinal, iliacal (including obturator fossa), perirectal, (ascending) 
retroperitoneal, axillary, mediastinal, supra or infraclavicular, and cervical).
patient collective and dataset generation. A final set of 549 patients fulfilled the inclusion criteria. An 
average of 4.72 ± 0.77 (SD) lymph nodes were segmented and labelled in each patient resulting in a total of 2,616 
labelled lymph nodes, with 431 of these labelled as positive for infiltration. Figure 2 shows how these images were 
used to generate test and training datasets, and is explained as follows. A set of 130 lymph nodes was set aside for 
testing all CNNs and experts. This test set was created by taking 15% of the available positive nodes (65 nodes) 
and matching with 65 randomly selected negative nodes to create a 50:50 class balanced set. The remaining 366 
positive nodes were matched with 366 randomly selected negative nodes to create a 50:50 class balanced set 
referred to as the ‘status balanced’ training set, with a total of 732 lymph nodes. The majority of lymph nodes in 
the status balanced and test dataset were in the inguinal region (32%), followed by the iliacal region (23%), and 
retroperitoneal region (19%). Figure 3a shows anatomical distribution by training set. To investigate effects of 
anatomical localization on classification results, the same 366 positive nodes used to create the status balanced 
set were sorted by anatomical category and matched to randomly selected negative nodes from within the same 
anatomical category, thus creating a 50:50 class balanced set with 548 lymph nodes, referred to as the ‘location 
balanced’ training set.
neural network training. Images were resampled to an isotropic resolution of 1 × 1 × 1 mm3. A volume of 
80 × 80 × 80 mm3 was cropped around the lymph node, centered at the center point of the manual lymph node 
segmentation. Image augmentation was performed online during model training, while only non-augmented 
images were provided to the model during validation and testing. A total of four random augmentations were 
performed: brightness was augmented by a factor between 0.5 and 1.5, after which images were rotated between 
±180 degrees, translated by a maximum of 5 voxels in the x, y and/or z axis, and finally flipped across the sagittal 
or axial plane or both. In order to ensure that no ‘black borders’ (i.e. areas with no image data due to rotation 
and shifting during augmentation) would be fed to the model, images were again cropped to a final volume of 
48 × 48 × 48 mm3. Finally, a single axial central slice was provided to the model as input.
Networks received two-dimensional images of 48 × 48 voxels and output a binary prediction whether or not 
the single lymph node displayed contained tumor or not. A final network architecture with 16 convolutional 
layers and three densely connected layers, inspired by the success of similar architectures by the Visual Geometry 
Group (VGGNet)21, was selected using k-fold validation with k = 10. Figure 4 shows the architecture used by all 
CNNs. CNNs were not pre-trained. Batch normalization was performed after every layer, with rectified linear 
units (ReLU) used as the activation function. The output of the convolutional layers was fed to a fully connected 
feed forward network with 3 hidden layers. Adam optimization was used to update network weights22, with 
parameters for alpha, beta1, beta2 and epsilon set at 0.0001, 0.9, 0.999 and 1e-08.
Three separate CNNs were trained. All models shared identical network architecture and were distin-
guished by the dataset used to train them: the status balanced model received status balanced CT images and 
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segmentations, the location balanced model received location balanced CT images, and the xMask model 
received status balanced CT images multiplied by their corresponding segmentation mask. All models were 
implemented in Keras and Tensorflow (v. 1.10.1) and run on a Nvidia TITAN Xp graphics card (NVIDIA Titan 
Xp, Rev A1, Santa Clara, CA, United States). Heatmaps were generated using the Innvestigate (v. 1.0.2) package23 
using the PatternAttribution method24.
Random forests. In order to validate neural network performance, random forests were generated to pre-
dict nodal infiltration status taking only nodal volume in mm3 and nodal anatomical location into account. Two 
random forests were trained for each of the training sets used (status balanced, location balanced). Anatomical 
location was encoded as a one hot vector. Random forests were implemented using the sklearn python package25 
with maximum depth set at 5 to prevent overfitting to the training data.
Study readers. Two radiologists, with at least 5 years of experience in urogenital imaging, were presented 
with all test CT images (n = 130). Radiologists were presented an 80 × 80 × 80 mm3 volume centered on the 
lymph node in question at 1 × 1 × 1 mm3 resolution, and were asked to categorize the likelihood of lymph node 
Figure 1. Generation of Labelled Dataset. (a) Imaging of a single patient with (1) a contrast-enhanced CT scan 
and (2) a 68Ga-PSMA PET scan. An average of 4.72 ± 0.77 lymph nodes were selected and semi-automatically 
segmented for each patient. A single lymph node positive for infiltration by PCa can be seen in the mediastinal 
region outlined in red in the CT image in (a1), and demarcated by a red arrow in PET scan in (a2). Using the 
68Ga-PSMA PET/CT as our reference standard, a label for infiltration status by prostate cancer (either positive 
or negative) was assigned on a per lymph node basis. (b) An example of a negative 68Ga-PSMA PET/CT image 
pair in which the centered lymph node does not exceed background. (c) An example of a positive image pair.
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infiltration by tumor from the following four categories: very unlikely, unlikely, likely, and very likely. Neither the 
segmentation, 68Ga-PSMA PET/CT images, nor label were provided.
Statistical analysis. Model performance was evaluated for each CNN on the independent test set (n = 130) 
using the area under curve (AUC) of the receiver operating characteristic (ROC) curve. AUCs and confidence 
intervals were calculated using the pROC package in R26, with confidence intervals computed using the bootstrap 
method with 10,000 stratified replicates. To allow for model comparison, the optimal threshold at which to con-
sider CNN output as positive was set by maximizing Youden’s index (sensitivity + specificity − 1), from which 
binary predictions were generated. Accuracy, sensitivity, specificity, PPV and NPV were calculated using the 
binary predictions. For study readers, the four categories were simplified to a dichotomous prediction of likely/
unlikely. AUC for each radiologist is equivalent to the average of specificity and sensitivity27. McNemar’s test was 
applied to all pairs of CNNs and experts. Results were considered statistically significant at a reduced P < 0.005 
level to correct for multiple comparison. All variables are given as mean along with standard deviation and range 
where applicable.
Results
Evaluation of CNN classifiers and experts. The best performing Neural Network was trained using the 
status balanced training set, with an AUC of 0.955 (95% CI from 0.923–0.987). The CNNs trained with datasets 
where implicit frequency data was stripped using 50:50 class balancing by location category (the location bal-
anced training set) or masking by the segmentation masks (xMask) performed comparably well, with an AUC of 
0.858 (95% CI from 0.793–0.922) and 0.863 (95% CI from 0.804–0.923), respectively. Setting the sensitivity at 90% 
for all CNN models, the specificities of status balanced, location balanced, and xMask models was 88%, 52%, and 
55%, respectively. Figure 5a shows ROC curves of all CNNs. Figure 5b shows histograms of CNN classification 
performance. Table 1 presents classification performance.
Figure 2. Dataset Generation Flowchart. Diagram describing generation of train and test datasets. Three 
train datasets shown, (status balanced, location balanced and xMask) were used to train three distinct neural 
networks. All neural networks and experts were tested and compared using a separate test set of 130 images, 
which was withheld from the neural networks during training. 50:50 class balancing was performed by taking 
all available infiltrated lymph nodes and randomly selecting an equally sized set of non-infiltrated lymph nodes, 
either from all available non-infiltrated nodes or from nodes within the same location category.
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The experienced uroradiologists achieved an average AUC, sensitivity, specificity and accuracy of 0.81, 65%, 
96% and 81% respectively. The first radiologist performed with a calculated AUC of 0.86, while the second radi-
ologist achieved a calculated AUC of 0.75. All differences in error rate between CNNs and expert readers was not 
statistically significant using McNemar’s test and p set at a reduced 0.005.
The random forest trained with the status balanced training set achieved an AUC, sensitivity, specificity and 
accuracy of 0.900, 84%, 95% and 90% respectively on the test set. The random forest trained with the location 
balanced set performed significantly worse with an AUC, sensitivity, specificity and accuracy of 0.654, 70%, 60% 
and 65% respectively on the test set.
Use of heatmaps to explain differences in performance. Using heatmaps, we sought to elucidate 
how deep learning achieves a high classification performance. Examples of heatmaps are shown in Figs. 6 and 7. 
It appears that the CNNs are able to learn features within the lymph node and more surprisingly, outside the 
Figure 3. Dataset Regional and Volume Distributions. (a) The final distribution of lymph node images by 
location and infiltration status for the two training sets, referred to as ‘status balanced’ with 732 images and 
‘location balanced’ with 548 images. (b) Boxplots depicting volume distribution for the location and status 
balanced training sets and test set grouped by infiltration status. Due to considerable overlap of the two 
distributions, size or volume is not a powerful indicator of infiltration.
Figure 4. Convolutional neural network architecture. All three CNNs developed shared a common architecture 
and differed by the data used for training. CNNs received 2D contrast-enhanced CT images and segmentation 
masks as input, with input images augmented randomly during training. All convolutional layers used a kernel 
size of 3 × 3. A rectified linear unit (ReLU) activation function followed by batch normalization was performed 
at every layer. Adam optimization was used to update network weights, with parameters for alpha, beta1, beta2 
and epsilon set at 0.0001, 0.9, 0.999 and 1e-08. Training was continued for 50 epochs.
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boundaries of the lymph node (such as the aorta or air/skin borders), that correlate with lymph node infiltration 
status. It is critical to note that our best performing model, trained on status balanced data, appears to rely on 
features outside of the lymph node in question. This can be most clearly seen on images of inguinal or mediastinal 
lymph nodes, where areas of skin/air border (often found in the inguinal region) or lung/mediastinum border 
contribute heavily to final classification output, and the lymph node centered in the image is not highlighted. 
Heatmaps from the same CNN show that the lymph node itself is more important in true positive considerations, 
suggesting that ‘inguinality’, i.e. features of the inguinal region are important considerations in a negative infiltra-
tion status. Heatmaps generated can also be diffuse, with CNN attention displayed in many regions of the image 
but not particularly focused on the lymph node or surrounding region.
Discussion
In this study we trained and tested three CNNs that predict metastatic infiltration of lymph nodes by PCa using 
contrast-enhanced CT images and assessed their performance versus that of experienced human readers. The 
CNNs performed at the same level of two expert radiologists.
Figure 5. Classification performance. (a) Shown are the ROC curves for the three trained CNNs on the 
separate test set (n = 130) with 95% confidence interval of the sensitivity at given specificities in shaded gray. 
Displayed in the lower right hand corner is the corresponding AUC. Classification by individual radiologists 
on the same test set are displayed as black dots. Blue stars show random forest performance on the separate 
test set using the corresponding training dataset (status or location balanced). (b) Histograms of CNN model 
classification performance on the test set. The threshold that maximizes Youden’s index is shown as a dashed 
line. The threshold which corresponds to a 90% sensitivity is shown as a dotted line. Infiltrated nodes (red bars) 
to the right of the given threshold are ‘true positive’, while those to the left are ‘false negative’: non-infiltrated 
nodes (blue) to the left are true negative, to the right are false positive.
Classifier AUC
Accuracy 
(%)
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
F1 
Score
CNN: Status 
Balanced 0.95 89 86 92 91 86 88
CNN: Location 
Balanced 0.86 80 72 89 87 76 78
CNN: xMask 0.86 76 76 76 76 76 76
RF: Status 
Balanced 0.90 90 84 95 94 86 89
RF: Location 
Balanced 0.65 65 70 60 63 67 67
Expert 1 0.86 86 80 93 92 82 85
Expert 2 0.75 74 50 98 97 66 66
Table 1. Classification performance. Classification results are displayed in percentages. The optimal threshold 
for the three CNNs was selected by maximizing Youden’s Index. RF: Random Forest.
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Current attempts at detecting lymph node metastases in PCa by radiological reading have been shown to 
be suboptimal, with a sensitivity and specificity shown in one study to be 42% and 82%, respectively6–8. Size is 
often the most relevant diagnostic criteria, with nodes greater than 10 mm deemed as suspicious and all below 
as benign9,10. Other criteria are difficult to quantify and are highly dependent on reader experience. Thus, the 
use of quantitative or algorithmic methods to detect LNI is desired. By radiomic analysis, in which a host of 
quantitative features are extracted from images and analyzed for statistical correlations, it has been suggested 
Figure 6. Heatmaps display neural network attention. (a) Contrast-enhanced CT images for two lymph nodes 
that were used as input to generate all heatmaps displayed, with (1) a retroperitoneal lymph node positive for 
infiltration by PCa, and (2) an inguinal lymph node negative for infiltration. In (b–d) heatmaps for the lymph 
nodes shown in (a), produced by three CNNs trained with status balanced training data, location balanced 
training data, or masked input data, respectively. CNN output, a pseudo probability score that the lymph 
node was classified as positive for tumor infiltration, is shown in the bottom right of each heatmap in (b–d). 
Stars signify true output predictions (either true positives for the lymph node in column 1 or true negative 
for column (2), with thresholds set by optimizing Youden’s index for each CNN, set at 34, 73 and 54 for b,c, 
and d respectively. Within heatmaps, light colors represent areas that contribute to output prediction, while 
dark regions contribute little to output prediction. CNNs often highlight regions within the lymph node that 
expert radiologists recognize as important for infiltration status, such as nodal center density and contrast 
enhancement. In true positive images it appears that high central density is the most relevant parameter in 
designating a ‘positive’ label. We postulate that the ‘halo’ surrounding the lymph node in the xMask CNN (d1), 
depicts the CNN attention to size. Heatmaps produced by the CNN trained with status balanced data highlight 
anatomical regions which aid in classification of lymph nodes, often demarcating the air-skin border seen in 
images of inguinal lymph nodes, as in b2.
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that a 7.5–Hounsfield CT density threshold could act as a surrogate parameter to differentiate LNI from benign 
processes28, with 89% of non-infiltrated LNs below this threshold and 92% infiltrated LN above, though this study 
used many different cancer types and a mix of PET tracers as a standard of reference. Deep learning, in which 
optimization algorithms are used to train neural network models in classification tasks, have shown mixed suc-
cess in detecting LNI. It has been previously found that CNNs are able to predict SUVmax in a PET scan using 
CT images of lymph nodes with a moderate accuracy, with an AUC of 0.8529. A number of studies predicting 
mediastinal LNI by lung cancer and breast cancer have been performed, with one study finding an AUC of 0.7630 
and another study classifying LNI in axillary lymph nodes by breast cancer achieving an AUC of 0.8431. CNNs 
were also found to classify head and neck tumor extranodal extension with an AUC of 0.91 using 3D CT images32. 
It has also been shown feasible to identify tumor infiltrated lymph nodes in MRI using deep learning33. To our 
knowledge, no study using deep learning to identify metastases of PCa into the lymphatic system by CT has been 
performed so far.
Generation of heatmaps is an attempt to explain how deep learning models reach classification decisions 
on a per-image basis, and represents a growing field of research known as ‘explainability’. Each heatmap can be 
interpreted as displaying CNN attention; regions of an input image that influenced the classification decision are 
demarcated. From the heatmaps produced in our study, it becomes clear that identical CNN architectures learn 
different methods to solve the same problem, depending on which data is used for training. It appears that the 
CNN trained with status balanced data learned not only to recognize features of the lymph node in question, but 
also to recognize anatomical features surrounding the lymph node. Using these anatomical features, it appears 
that the status balanced CNN implicitly learned frequency of infiltration in different anatomical regions and used 
these frequencies or probabilities to improve output prediction. For example, in the status balanced dataset, 91% 
of inguinal lymph nodes were negative (see Fig. 3a). Thus, labeling all inguinal lymph nodes as negative is highly 
rewarded during the training process, and recognizing ‘inguinality’ aided in achieving high classification accu-
racy. Indeed, the air/skin border found in inguinal lymph nodes was often well demarcated in heatmaps, as seen 
in Fig. 6. However, it is unclear to what extent such anatomical features influenced classification; the CNN trained 
Figure 7. Limitations of heatmaps as tool to explain black box predictions. (a) Contrast-enhanced CT images 
for two inguinal lymph nodes that were used as input to generate all heatmaps displayed, with (1) a lymph node 
positive for infiltration by PCa, and (2) a lymph node negative for infiltration. In (b,c) heatmaps produced by 
two CNNs trained with location balanced training data, or masked input data, respectively. Beyond verifying 
that the lymph node is important for classification, heatmaps provide little additional information as to why 
classification output was either true positive (b1,c1), true negative (b2), or false positive (c2).
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with status balanced data did classify some inguinal lymph nodes as positive, and some retroperitoneal lymph 
nodes (of which 94% were positive in the status balanced dataset) as negative, as shown in Fig. 5b. The fact that 
learning anatomical features within the image (as proxy for anatomical location) greatly improves classification 
performance in the status balanced dataset is underscored by the high performance of the random forest trained 
on the this dataset; using nodal volume and location alone, high classification performance was achieved (AUC 
0.90). Thus, our best performing neural network is most likely essentially useless on external datasets not sharing 
the anatomical bias found in the status balanced dataset.
We created two additional CNNs to eliminate anatomical clues within images in an attempt to force neural 
network attention to the lymph node. First, we created a new training dataset created by balancing positive and 
negative lymph nodes within each location category. By doing so we eliminated the possibility of learning infil-
tration frequency at each anatomical location. While it is clear from generated heatmaps that the CNN trained 
with this location balanced set did focus more on the lymph node and not on anatomical features, it was not able 
to achieve the same classification performance as the status trained CNN. However, a random forest receiving 
nodal volume and location information trained on this location balanced dataset performed poorly, considerably 
worse than the CNN (AUC 0.677 vs 0.858). This leads us to believe that the neural network is indeed focusing on 
features within the lymph node to perform classification. Secondly, a new CNN was provided images created by 
multiplying the CT image by the manually generated segmentation (xMask), thus setting all values outside of the 
lymph node to zero. This removed all contextual information, such as location in the body or presence of neigh-
boring structures. The resulting performance was similar to the location balanced CNN. Interestingly, heatmaps 
created by the xMask CNN often showed a diffuse halo like pattern of attention outside of the lymph borders, 
which we postulate may be the CNNs attention to size. We cannot definitively state that any of the CNNs devel-
oped are able to determine nodal size due to intrinsic limitations of heatmaps as an explainability tool and the 
black box nature of neural networks, which often created very similar looking heatmaps (see Fig. 7). Regardless, 
size alone is a poor predictor of infiltration, as can be intuited by the considerable overlap of volume distributions 
for lymph nodes positive and negative for infiltration (see Fig. 3b) and shown quantitatively by the poor perfor-
mance of the random forests trained with location balanced data.
There are a number of limitations to our study. It is important to note that the usage of PSMA PET/CT is an 
imperfect method of label generation. In comparison to the gold standard for detecting LN metastases, namely 
histopathological analysis after extended pelvic lymph node dissection (PLND)34, PSMA PET/CT was found 
to have a sensitivity of 80% and specificity of 97% in a systematic review and meta-analysis15,16,35,36. Due to the 
high specificity, it is unlikely that our models were trained with large numbers of false positive lymph nodes. In 
addition, we relied on manual detection of segmentation of lymph nodes, and we do not perform lymph node 
detection. The tendency to select easily definable and large lymph nodes for analysis led to a large amount of 
inguinal lymph nodes being included in our dataset, a limitation we sought to overcome by various means of class 
balancing.
The obvious attention to anatomical features demonstrated by our best performing CNN raises a number 
of issues in the implementation of deep learning in the medical field. Deep learning models are able to learn 
frequencies and summary statistics, known as biases, within datasets, which can lead to high classification per-
formance based upon undesirable features. This problem is distinct from overfitting to the training dataset, and 
instead points to the need for a more rigorous explainability of deep learning models. Our results represent a 
moderate success in the use of saliency maps (heatmaps), as through this instance-based analysis of CNN atten-
tion, we were able to determine that our best performing model was using anatomical features of the lymph node 
environment in addition to features within the lymph node. We were able to compensate for anatomical variations 
in infiltration frequency because we had collected coarse data on anatomical location. However, not only does 
class balancing at ever higher levels of abstraction encroach on the notion of ‘automated feature generation’, it 
is not feasible in the medical field due to lack of knowledge of what constitutes a relevant category. The lack of 
explainability methods for deep learning models is also a limitation. Our use of heatmaps, known as an attribu-
tion method, of which there are several, is problematic not just because of inconsistencies in implementation and 
performance24, but the underpinning assumption that individual pixels in an input image should be the primary 
unit of relevance for classification.
Current deep learning systems can perform remarkably well and will most likely continue to improve with 
larger datasets and access to more contextual information, such as blood serum values and genomic data. Our 
results show that CNNs are capable of classifying lymphatic infiltration by PCa on contrast-enhanced CT scans 
alone as compared to the 68Ga-PSMA PET/CT reference standard. Anatomical context influences the performance 
of CNNs and should be carefully considered when building such imaging based biomarkers.
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AG, Tübingen, Curis, Daiichi, DC Devices, Inc. USA, Delcath Systems, Dermira Inc. Deutsche Krebshilfe, 
Deutsche Rheuma Liga, DFG, DSM Nutritional Products AG, Dt. Stiftung für Herzforschung, Dynavax, Eisai 
Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Eli Lilly and Company Ltd. EORTC, Epizyme, 
INC., Essex Pharma, EU Programmes, Euroscreen S.A., Fibrex Medical Inc., Foxused Ultrasound Surgery 
Foundation, Fraunhofer Gesellschaft, Galena Biopharma, Galmed Research and Development Ltd., Ganymed, 
GE, Genentech Inc., GETNE (Grupo Espanol de Tumores Neuroendocrinos), Gilead Sciences, Inc, Glaxo 
Smith Kline, Glycotope GmbH, Berlin, Goethe Uni Frankfurt, Guerbet, Guidant Europe NV, Halozyme, 
Hewlett Packard GmbH, Holaira Inc. ICON (CRO), Idera Pharmaceuticals, Inc., Ignyta, Inc. Immunomedics 
Inc., Immunocore, Incyte, INC Research, Innate Pharma, InSightec Ltd., Inspiremd, inVentiv Health Clinical 
UK Ltd., Inventivhealth, IOMEDICO, IONIS, IPSEN Pharma, IQVIA, ISA Therapeutics, Isis Pharmaceuticals 
Inc., ITM Solucin GmbH, Jansen, Kantar Health Gmbh (CRO), Kartos Therapeutics, Inc., Karyopharm 
Therapeutics, Inc., Kendle/MorphoSys Ag, Kite Pharma, Kli Fo Berlin Mitte, La Roche, Land Berlin, Lilly 
GmbH, Lion Biotechnology, Lombard Medical, Loxo Oncology, Inc., LSK BioPartners; USA, Lundbeck GmbH, 
Lux Biosciences, LYSARC, MacroGenics, MagForce, MedImmune Inc., Medpace, Medpace Germany GmbH 
(CRO), MedPass (CRO), Medronic, Merck, Merromack Pharmaceuticals Inc., MeVis Medical Solutions AG, 
Millennium Pharmaceuticals Inc., Mologen, Monika Kutzner Stiftung, MSD Sharp, NeoVacs SA, Newlink 
Genentics Corporation, Nexus Oncology, NIH, Novartis, novocure, Nuvisan, Ockham oncology, OHIRC 
Kanada, Orion Corporation Orion Pharma, Parexel CRO Service, Perceptive, Pfizer GmbH, Pharma Mar, 
Pharmaceutical Research Associates GmbH (PRA), Pharmacyclics Inc., Philipps, PIQUR Therapeutics 
Ltd., Pluristem, PneumRX.Inc, Portola Pharmaceuticals, PPD (CRO), PRAint, Premier-research, Provectus 
Biopharmaceuticals, Inc., psi-cro, Pulmonx International Sàrl, Quintiles GmbH, Regeneron Pharmaceuticals, 
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